RESUMO
Introduction: Infection with vancomycin-resistant Enterococcus spp (VRE) has been a worldwide problem since mid 1980s and, in Brazil, since 1996. This study was conducted to evaluate the experience with VRE in our institution. Methods: A prospective cohort study from 2000 to 2009 was conducted at Hospital São Lucas da PUCRS. All hospitalized patients with VRE positive culture were included and followed from their diagnosis until they were negative for VRE or their discharge. Only the first admission for each VRE positive patient was included. Pulsed field gel electrophoresis (PFGE) was performed to determine how VRE had spread. Results: A total of 315 cases of VRE were identified, 224 of which were isolated from rectal swabs. Vancomycin-resistant/ampicilin susceptible Enterococcus faecalis were identified in 312 isolates. PFGE was performed in 47 VRE isolates that presented an indistinguishable migratory profile. The median length of hospital stay and length of stay before VRE isolation were 46 days and 21 days, respectively; 52% of the patients were aged 60 and above. The annual distribution of the new VRE cases showed a clear decrease from 2000 to 2009. Discussion: This study shows a substantial VRE colonization (71%) with a homogenous pattern that emphasizes its transversal spread. Predominance of E. faecalis differs from the literature which largely describes a higher prevalence of vancomycin-resistant Enterococcus faecium. The follow up of VRE during 9 years in our institution highlighted the importance of continuous surveillance to prevent outbreaks in our hospital.
Assuntos
Humanos , Seguimentos , Estudos Prospectivos , Enterococos Resistentes à Vancomicina , Enterococcus faecalis , Enterococcus faecium , Controle de InfecçõesRESUMO
Chronic kidney disease (CKD) is becoming a major public health issue worldwide, mainly due to the increasing prevalence of hypertension, diabetes and aging population. Chronic hepatitis C virus (HCV) infection commonly involves the kidneys, can be a cause of CKD, and significantly impacts morbidity and mortality in these patients. Prompt recognition and knowledge of how to best manage these patients are essential in order to have a successful renal outcome. Patients with HCV and kidney involvement can often be managed with a specific combination of antiviral drugs, immunosuppressants, plasmapheresis, and newer monoclonal antibodies. However, no large randomized controlled trials have been conducted in this patient population, optimal management of HCV-mediated kidney diseases is not well defined, and treatment itself can be associated with significant toxicity in patients with CKD. This article reviews the recent literature, discusses the limitations of current therapies, as well as toxicity associated with treatment, and suggests future areas for research.
Assuntos
Antivirais/uso terapêutico , Hepacivirus , Hepatite C Crônica/tratamento farmacológico , Falência Renal Crônica/virologia , Corticosteroides/uso terapêutico , Anticorpos Monoclonais Murinos/uso terapêutico , Antivirais/efeitos adversos , Quimioterapia Combinada , Hepatite C Crônica/complicações , Humanos , Fatores Imunológicos/uso terapêutico , Interferon alfa-2 , Interferon-alfa/efeitos adversos , Interferon-alfa/uso terapêutico , Polietilenoglicóis/efeitos adversos , Polietilenoglicóis/uso terapêutico , Proteínas Recombinantes/efeitos adversos , Proteínas Recombinantes/uso terapêutico , Ribavirina/efeitos adversos , Ribavirina/uso terapêutico , RituximabRESUMO
After the introduction of routine treatment for every nasal carrier of methicillin-resistant Staphylococcus aureus, active follow-up surveillance for nosocomial methicillin-resistant S. aureus infection was conducted for 5 years in an intensive care unit of a tertiary-care teaching hospital. There was a significant decrease in the incidence of nosocomial methicillin-resistant S. aureus infection during the later years of follow-up. Decolonization of nasal carriers of methicillin-resistant S. aureus is probably associated with such findings.
Assuntos
Antibacterianos/administração & dosagem , Anti-Infecciosos Locais/administração & dosagem , Clorexidina/administração & dosagem , Unidades de Terapia Intensiva , Resistência a Meticilina , Mupirocina/administração & dosagem , Nariz/microbiologia , Infecções Estafilocócicas/epidemiologia , Staphylococcus aureus , Antibacterianos/uso terapêutico , Anti-Infecciosos Locais/uso terapêutico , Brasil , Clorexidina/uso terapêutico , Infecção Hospitalar/prevenção & controle , Humanos , Controle de Infecções/métodos , Mupirocina/uso terapêutico , Pomadas , Infecções Estafilocócicas/prevenção & controle , Staphylococcus aureus/efeitos dos fármacosRESUMO
Este artigo aborda as principais causas de linfadenopatias dividindo-as em agudas e crônicas, localizadas e generalizadas. É estabelecida uma sequência de investigaçäo incluindo exame clínico, exames complementares e exame do linfonodo.
Assuntos
Humanos , Doenças Linfáticas , Doenças Linfáticas/diagnóstico , Doenças Linfáticas/etiologiaRESUMO
Aspectos clínicos, fisiopatológicos, histopatológicos e terapêuticos de doenças sistêmicas que comprometem o rim säo descritos sumariamente. A revisäo da literatura se destina a dar uma orientaçäo a estudantes e generalistas para o estudo deste importante grupo de patologias: como exemplos, as nefropatias do diabete, lupus eritematoso sistêmico, mieloma múltiplo e amiloidose säo abordadas